Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: Results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

British Journal of Cancer

Volumn 107, Issue 8, 2012, Pages 1257-1267

  Earl, H M ^a,b   Hiller, L ^c   Dunn, J A ^c   Vallier, A L ^d   Bowden, S J ^e   Jordan, S D ^e   Blows, F ^a   Munro, A ^f   Bathers, S ^e   Grieve, R ^g   Spooner, D A ^h   Agrawal, R ⁱ   Fernando, I ^h   Brunt, A M ^j   O'Reilly, S M ^k   Crawford, S M ^l   Rea, D W ^e   Simmonds, P ^m   Mansi, J L ^n,o   Stanley, A ⁿ   McAdam, K ^d,p   Foster, L ^q   Leonard, R Cf ^r   Twelves, C J ^s   Cameron, D ^t   Bartlett, J Ms ^f   Pharoah, P ^u   Provenzano, E ^a,b   Caldas, C ^a,b   Poole, C J ^v   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NIHR Cambridge Biomedical Research Centre   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^h QUEEN ELIZABETH HOSPITAL   (United Kingdom)

ⁱ ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^k CLATTERBRIDGE HOSPITAL   (United Kingdom)

^l AIREDALE GENERAL HOSPITAL   (United Kingdom)

^m ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

ⁿ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^o KING'S COLLEGE LONDON   (United Kingdom)

^p PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^q Scottish Cancer Therapy Network   (United Kingdom)

^r CHARING CROSS HOSPITAL   (United Kingdom)

^s UNIVERSITY OF LEEDS   (United Kingdom)

^t WESTERN GENERAL HOSPITAL   (United Kingdom)

^u UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^v Clinical Sciences Research Institute   (United Kingdom)

more..

Author keywords

Adjuvant chemotherapy; Anthracyclines; Breast cancer; Classical CMF; Epirubicin; NEAT

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PROGNOSIS; CENTROMERE; CHROMOSOME 17; CHROMOSOME DUPLICATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EARLY CANCER; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; UNIVARIATE ANALYSIS;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MEDICATION ADHERENCE; METHOTREXATE; MIDDLE AGED;

EID: 84867379438     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.370     Document Type: Article

References (28)

1. Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ (2010) Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 11(3): 266-274
2. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, HeikkiläP, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. Plos Med (2010) 7(5): e1000279, pages 1-12
3. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304(1): 10-15 (Pubitemid 11212891)
4. Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 274(10): 796-797
5. Bonadonna G, Zambetti M, Moliterni A, Gianni L, Valagussa P (2004) Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer J Clin Oncol 22(9): 1614-1620 (Pubitemid 41079799)
6. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M (1991) Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9(12): 2134-2140
7. Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher M (2011) The costeffectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer 47(17): 2517-2530
8. Coombes RC, Bliss JM, Wils J, Morvan F, EspiéM, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Pérez-López FR, Vassilopoulos P, Ferreira EP, Chilvers CE, Coombes G, Woods EM, Marty M (1996) Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14(1): 35-45
9. Cox DR (1972) Regression models and lifetables. J R Stat Soc (B) 34 187-220
10. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M, HER2/TOP2A Meta-analysis Study Group (2011) Meta-analysis of HER-2 and Topoisomerase IIa as predictive biomarkers for anthracycline benefit: definitive individual patient data analysis from five randomised clinical trials of CMF versus anthracycline-based adjuvant therapy in early breast cancer. Lancet Oncol 12(12): 1134-1142
11. Earl HM, Iddawela M (2004) Epirubicin as adjuvant breast cancer treatment. Expert Rev Anticancer Therapy 4(2): 189-195 (Pubitemid 38477333)
12. Earl HM, Hiller L, Dunn JA, Bathers S, Harvey P, Stanley A, Grieve RJ, Agrawal RK, Fernando IN, Brunt AM, McAdam K, O'Reilly S, Rea DW, Spooner D, Poole CJ, NEAT Investigators (2008) NEAT: National Epirubicin Adjuvant Trial-Toxicity, Delivered Dose Intensity and Quality of Life. Br J Cancer 99(8): 1226-1231
13. Early Breast Cancer Trialists' Collaborative Group (1990) Treatment of Early Breast Cancer. Vol 1, Worldwide evidence 1985-1990, Oxford University Press: Oxford, England
14. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic therapy of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences, and 24,000 deaths among 75,000 women. Lancet 339: 71-85
15. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
16. Engelsman E, Klijn JC, Rubens RD, Wildiers J, Beex LV, Nooij MA, Rotmensz N, Sylvester R (1991) 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 27(8): 966-970
17. Goldie JH, Coldman AJ, Gudauskas GA (1982) 1 Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66(3): 439-449 (Pubitemid 12084933)
18. Habeshaw T, Paul J, Jones R, Stallard S, Stewart M, Kaye SB, Soukop M, Symonds RP, Reed NS, Rankin EM (1991) Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomised trial. J Clin Oncol 9: 295-304
19. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM (1998) Time-dependence of hazard ratios of prognostic factors in primary breast cancer. Breast Cancer Res Treat 52: 227-237 (Pubitemid 29056098)
20. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
21. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomised trial of intensive cyclophosphamide, epirubicin, and fluorouracil compared with cyclophosphamide, methotrexate and fluorouracil in pre-menopausal women with node-positive breast cancer. J Clin Oncol 16: 2651-2658 (Pubitemid 28363028)
22. Moliterni A, Bonadonna G, Valagussa P, Ferrari L, Zambetti M (1991) Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9(7): 1124-1130
23. Norton L, Day R 1991) Potential innovations in scheduling of cancer chemotherapy. Important Adv Oncol 57-72
24. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human tumours. Nature 406(6797): 747-752
25. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ, NEAT Investigators and the SCTBG (2006) Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. N Engl J Med 355: 1851-1862 (Pubitemid 44664643)
26. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23(18): 4179-4191 (Pubitemid 46211324)
27. Rea DW, Hiller L, Earl HM, Dunn JA, Bathers S, Spooner D, Grieve R, Agrawal RK, Poole CJ, on behalf of the NEAT Investigators (2004) Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: a non-randomised comparison of patients treated in the National Epirubicin Adjuvant trials (NEAT). J Clin Oncol 22, 14(s): abstract 595
28. Retsky MW, Demicheli R, Hrushesky WJ, Baum M, Gukas ID (2008) Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 116(7-8): 730-741